Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes

Oct 19, 2026

Upload by dawugda

12-week sodium-glucose cotransporter-2 inhibition with dapagliflozin 10 mg daily was assessed for effects on vascular stiffness, cardiac and kidney function, and neurohormonal pathways in participants at cardiovascular risk, with or without type 2 diabetes. In a randomized, double-blind, placebo-controlled parallel study of 51 participants, vascular arterial stiffness decreased after 12 weeks. Extracellular fluid and thoracic fluid content reductions persisted, while measured glomerular filtration rate declined with compensatory sodium-handling changes. The study suggests early cardiorenal effects without established clinical protection, supporting trials in lower-risk settings.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages17

Reading Time43 min

AccessFree to download

Background

Methods

Results

Conclusions

Registration

Key Words

University of Groningen Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes Sridhar, Vikas S; Kugathasan, Luxcia; Lytvyn, Yuliya; Deng, Yangqing; Liu, Hongyan; Lovblom, Leif Erik; Tse, Josephine; Nardone, Massimo; Floras, John S; Osuntokun, Tosin Published in: Hypertension DOI: 10.1161/HYPERTENSIONAHA.125.25955 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2026 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Sridhar, V. S. , Kugathasan, L. , Lytvyn, Y. , Deng, Y. , Liu, H. , Lovblom, L. E. , Tse, J. , Nardone, M. , Floras, J. S. , Osuntokun, T. , Tobushi, T. , Lam, R. C. Y. , Lam, B. , Stevens, J. , Burger, D. , Touw, D. J. , Heerspink, H. J. L. , Lovshin, J. A. , Perkins, B. A. , & Cherney, D. Z. I. (2026) . Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension , 83(2), Article e25955 . [https://doi.org/10.1161/HYPERTENSIONAHA.125.25955](https://doi.org/10.1161/HYPERTENSIONAHA.125.25955) Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons) . The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: [https://www.rug.nl/library/open-access/self-archiving-pure/taverne](https://www.rug.nl/library/open-access/self-archiving-pure/taverne)amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/U MCG research database (Pure): [http://www.rug. nl/research/portal. For technical reasons the](http://www.rug. nl/research/portal. For technical reasons the)[ ](http://www.rug. nl/research/portal. For technical reasons the)[number of authors shown on this cover page is limited to 10 maximum.](number of authors shown on this cover page is limited to 10 maximum.) Download date: 19-10-2026 Downloaded from [http://ahajournals.org by on May 20](http://ahajournals.org by on May 20), 2026 Hypertension ORIGINAL ARTICLE | Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
Vikas S. Sridhar,* Luxcia Kugathasan,* Yuliya Lytvyn, Yangqing Deng, Hongyan Liu, Leif Erik Lovblom, Josephine Tse, Massimo Nardone, John S. Floras, Tosin Osuntokun, Tomoyuki Tobushi, Ruthabella C.Y. Lam, Brian Lam, Jasper Stevens, Dylan Burger, Daan J. Touw, Hiddo J.L. Heerspink, Julie A. Lovshin, Bruce A. Perkins, David Z.I. Cherney
BACKGROUND: We investigated the impact of 12 weeks of sodium-glucose cotransporter-2 inhibition (dapagliflozin 10 mg daily) on vascular stiffness, cardiac and kidney function, and neurohormonal pathways in participants at cardiovascular risk.
METHODS: This randomized double-blind, parallel-group, placebo-controlled study enrolled 51 participants with at least 1 established cardiovascular condition or cardiovascular risk factor. Participants underwent 3 sequential assessments under clamped euglycemia (4–6 mmol/L): at baseline, at 1 week and 12 weeks of treatment. The primary outcome was vascular arterial stiffness, quantified as augmentation index and pulse-wave velocity. Secondary

FAQs

What was the primary outcome in this trial?

The primary outcome was vascular arterial stiffness, quantified using augmentation index and pulse-wave velocity.

How did dapagliflozin affect vascular stiffness after 12 weeks?

Dapagliflozin decreased vascular arterial stiffness, reflected by a placebo-adjusted reduction in aortic augmentation index after 12 weeks.

What changes occurred in kidney function and sodium handling?

Measured glomerular filtration rate decreased, alongside acute increases in proximal sodium excretion and other indices of distal sodium reabsorption, with increased urine adenosine.

Oct 19, 2026

Upload by dawugda